Comparative Performance Evaluation of FilmArray BioFire RP2.1 and MAScIR 2.0 Assays for SARS-CoV-2 Detection

Tazi, Sophia; Kabbaj, Hakima; Zirar, Jalila; Zouaki, Amal; Amin, Ghizlane El; Himeur, Othman El; Seffar, Myriam

doi:10.1155/2022/4510900

Cited by 10 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, a single retrospective study, recently published and carried out in our laboratory, evaluated the FilmArray BioFire RP2.1 (Respiratory 2.1 Panel) kit using our MAScIR SARS-CoV-2 M 2.0 kit as a reference kit [ 18 ]. In this study, there were no discordant results between MAScIR and FilmArray BioFire RP2.1 with regards to negative samples.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the MAScIR SARS-CoV-2 M Kit 2.0 on the SARS-CoV-2 Infection

Zouaki

Kabbaj

Amin

et al. 2023

Advances in Virology

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2 is a major public health problem worldwide. Since its emergence, several diagnostic kits have been developed to ensure rapid patient management. The aim of our study is to check the performance of the new Moroccan SARS-CoV-2 detection kit: MAScIR SARS-CoV-2 M 2.0. The following parameters were studied: repeatability, reproducibility, analytical specificity, analytical sensitivity, and comparison with the GeneFinder™ COVID-19 Plus RealAmp Kit. In addition, an external quality evaluation comprising five specimens was carried out as part of an international program for the external quality evaluation of sublaboratories of the WHO and the Laboratory Office of the National Institute of Hygiene of Morocco. The results of all parameters studied showed an analytical performance that complied with the requirements of the method verification/validation protocol adopted by the Central Laboratory of Virology and met the recommendations of COFRAC (French Accreditation Committee). During the current study, the sequencing of some randomly selected positive samples was performed, among which the carriers of the Alpha variant, the Delta variant, and the Omicron variant were detected. These results allowed us to deduce that this kit was valid for detecting these three variants.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the MAScIR SARS-CoV-2 M Kit 2.0 on the SARS-CoV-2 Infection

Zouaki

Kabbaj

Amin

et al. 2023

Advances in Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, Lade H et al indicated that the FilmArray TM RP assay is easy to work and provide rapid identification of respiratory viruses [ 57 ]. Moreover, Tazi S et al [ 31 ] showed that the estimated sensitivity and specificity of FilmArray, compared with the MAScIR SARS-CoV-2 M kit 2.0, were 100% and 79.2%, respectively. Recently, Livingstone et al [ 58 ] showed that the application of FilmArray TM RP 2.1 assay for COVID-19 remarkably reduced the time to obtain results spent on assessment cohort wards and the proportion of hospital-acquired COVID-19 infection.…”

Section: Discussionmentioning

confidence: 99%

“…A qualitative result for each target was automatically interpreted by the software according to the endpoint melting curve data. A pathogen was recorded as detected if at least one of its corresponding assays was positive [ 31 ].…”

Section: Methodsmentioning

confidence: 99%

Distribution of Viral Respiratory Infections during the COVID-19 Pandemic Using the FilmArray Respiratory Panel

Chen

2022

Biomedicines

View full text Add to dashboard Cite

This study was conducted to evaluate the distribution of respiratory viral pathogens in the emergency department during the coronavirus disease 2019 (COVID-19) pandemic. Between May 2020 and September 2022, patients aged between 0.1 and 98 years arrived at the emergency department of Asia University Hospital, and samples from nasopharyngeal swabs were tested by the FilmArrayTM Respiratory Panel (RP). SARS-CoV-2 positivity was subsequently retested by the cobas Liat system. There were 804 patients for whom the FilmArrayTM RP was tested, and 225 (27.9%) of them had positive results for respiratory viruses. Rhinovirus/enterovirus was the most commonly detected pathogen, with 170 (61.8%) cases, followed by adenovirus with 38 (13.8%), SARS-CoV-2 with 16 (5.8%) cases, and coronavirus 229E, with 16 (5.8%) cases. SARS-CoV-2 PCR results were positive in 16 (5.8%) cases, and there were two coinfections of SARS-CoV-2 with adenovirus and rhinovirus/enterovirus. A total of 43 (5.3%) patients were coinfected; the most coinfection was adenovirus plus rhinovirus/enterovirus, which was detectable in 18 (41.9%) cases. No atypical pathogens were found in this study. Intriguingly, our results showed that there was prefect agreement between the detection of SARS-CoV-2 conducted with the cobas Liat SARS-CoV-2 and influenza A/B nucleic acid test and the FilmArrayTM RP. Therefore, the FilmArrayTM RP assay is a reliable and feasible method for the detection of SARS-CoV-2. In summary, FilmArrayTM RP significantly broadens our capability to detect multiple respiratory infections due to viruses and atypical bacteria. It provides a prompt evaluation of pathogens to enhance patient care and clinical selection strategies in emergency departments during the COVID-19 pandemic.

show abstract

“…However, Tazi et al compared two PCR assays, BioFire RP2.1 plus and their laboratory's reference test, MAScIR SARS-CoV-2 M kit 2.0, a triplex real-time RT-PCR, using TaqMan technology, targeting SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and S genes. 5 The results were compared, and each discrepant sample with sufficient volume underwent a third test using ARGENE® SARS-CoV-2 R-GENE kit, a triplex real-time RT-PCR, which also used TaqMan technology, targeting SARS-CoV-2 N (Nucleocapsid) and RdRp genes. Of the 80 specimens positive for BioFire RP2.1 Plus, 21 (26.3%) had discordant results on MAScIR, and only 11 could be tested on ARGENE, revealing negative results in five cases.…”

mentioning

confidence: 99%

“… 4 These results led to them consequently retaining the SARS-CoV-2 positive results of these discordant samples on BioFire RP2.1 plus, regardless of the detection of one or both targets. 5 …”

mentioning

confidence: 99%